Blood Cell Factors Market Expected to Touch USD 4.31 Bn by 2032, CAGR of 3.6% Detailed in New Report

The global blood cell factors market growth is driven by the increasing prevalence of blood disorders, advancements in healthcare infrastructure, and rising demand for effective treatments. Additionally, growing awareness about blood cell factors and their role in treating various blood-related conditions are expected to fuel the market growth.
Blood Cell Factors Market Insights
The Blood Cell Factors industry is experiencing robust expansion driven by rising hemophilia treatment demand and novel biologics pipelines. This expert analysis explores market size, dynamics, and actionable insights to guide strategic decision-making in 2025–2032.
The Global Blood Cell Factors Market size is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032. According to the latest Blood Cell Factors market size assessment and Blood Cell Factors market report, global market revenue surpassed USD 3.4 Bn in 2024, indicating an upward shift in market share across major regions. This market forecast underscores expanding industry size and business growth opportunities.
Market Key Takeaways:
Region:
• North America: Strong R&D investments in recombinant factors drive advanced product launches.
• Latin America: Rising healthcare infrastructure improvements accelerate treatment adoption.
• Europe: Regulatory harmonization fosters cross-border supply chains.
• Asia Pacific: Expanding manufacturing capacity and favorable pricing boost volume.
• Middle East: Government-backed hemophilia programs underpin demand growth.
• Africa: Emerging import channels and NGO support enhance access.
Segment Covers:
• Product Type:
– Recombinant Factors: Example: Amgen's 2024 launch of Factor VIII rAHFV captured 42% of new biologics uptake.
– Plasma-Derived Factors: Sanofi's Purified FVIII retains stable pricing leadership in 2025.
– Gene Therapy Platforms: Early-stage pipelines by Regeneron target one-dose cures.
• Application:
– Hemophilia A/B: Eli Lilly's factor IX pegylated formulation grew 28% in 2024 revenues.
– Von Willebrand Disease: Pfizer's new multi‐domain VWF therapy gained EMA approval in 2024.
• End User:
– Hospitals & Clinics: Accounted for 65% of procurement in 2024.
– Specialty Centers: Focused infusion protocols drive repeat purchase patterns.
Growth Factors:
• Rising Prevalence of Coagulation Disorders: The global hemophilia population increased by 4.5% between 2023 and 2024, driving factor consumption.
• Strategic Partnerships: In 2024, Roche's collaboration with a biotech startup increased manufacturing capacity by 15% and expanded contract manufacturing revenue by USD 80 Mn.
• Blood Cell Factors market share gains hinge on targeted rebates and patient support programs in North America and Europe, lifting volume growth despite pricing pressures.
• Increased public funding for rare diseases in Japan and Australia boosted factor adoption by 12% in 2024.
Book the Latest Edition of this Market Study Get Up to 25 % Discount: https://www.coherentmarketinsights.com/insight/buy-now/7942
Market Trends:
• Personalized Medicine: Tailored dosing algorithms using AI-driven pharmacokinetic models reduced bleed rates by 30% in 2024 trials.
• Biosimilar Entrants: Novartis's pipeline biosimilar of FVIII (expected 2025 launch) is projected to undercut reference pricing by 20%.
• Digital Adherence Tools: Mobile infusion tracking apps improved on-time dosing by 18% across 2024 real-world studies.
• Blood Cell Factors market trends indicate heightened M&A activity—with Teva's acquisition of a plasma facility in 2024 enhancing Asia Pacific supply by 25%.
Actionable Insights:
• Production Capacity: Global recombinant factor capacity rose to 150 kg in 2024, up 10% YOY, enabling wider supply.
• Pricing Benchmarks: Median USD 0.85/IU for FVIII in Western Europe vs. USD 0.65/IU in Asia Pacific illustrates import-driven discounts.
• Exports & Imports: Asia Pacific exported USD 220 Mn of plasma-derived factors in 2024, while Africa imported USD 90 Mn, reflecting demand-supply gaps.
• Use-Case Volumes: Hospital procurement volumes for prophylactic regimens grew 14% in Latin America in 2024, outpacing on-demand therapy.
• Nano-Indicators: Patient registry expansions in the Middle East added 5,000 new documented cases in 2024, informing localized forecasting models.
• Blood Cell Factors market revenue analyses highlight cost-per-patient as a leading macro-indicator for future investment.
Key Players:
• Amgen Inc.
• Johnson & Johnson
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Eli Lilly Company
• Gilead Sciences Inc.
• Sanofi S.A.
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Celgene Corporation
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
Get Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/7942
Competitive Strategies:
– Roche's 2024 capacity partnership with Biogen boosted contract revenues by USD 80 Mn and reduced production costs by 12%.
– Novartis's biosimilar rollout strategy undercut reference FVIII pricing by 20%, capturing 8% market share in Europe within six months.
– Pfizer's bundled care agreements with specialty clinics in North America in 2024 increased annualized purchases by 22%.
Frequently Asked Questions
1. Who are the dominant players in the Blood Cell Factors market?
Major players include Amgen, Roche, Novartis, Pfizer, and Sanofi, each commanding significant market share through diversified portfolios and strategic alliances.
2. What will be the size of the Blood Cell Factors market in the coming years?
The market is forecast to grow from USD 3.37 Bn in 2025 to USD 4.31 Bn by 2032 at a 3.6% CAGR.
3. Which end-user industry has the largest growth opportunity?
Hospitals & clinics represent the largest segment, accounting for over 65% of revenues in 2024, driven by prophylactic treatment mandates.
4. How will market development trends evolve over the next five years?
Trends include AI-enabled dosing, gene therapy maturation, and biosimilar price competition, reshaping market dynamics and business growth strategies.
5. What is the nature of the competitive landscape and challenges in the Blood Cell Factors market?
Intense R&D races, biosimilar threats, and supply-chain complexities define the competitive landscape, while high manufacturing costs remain a key restraint.
6. What go-to-market strategies are commonly adopted in the Blood Cell Factors market?
Strategies include co-development partnerships, patient support services, value-based contracts, and digital adherence platforms to drive uptake and retention.
About Coherent Market Insights
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

National Post

2 hours ago

• National Post

Combined Shareholders' Meeting of June 19, 2025: All Submitted Resolutions Were Adopted

Article content NEUILLY-SUR-SEINE, France — The Combined Shareholders' Meeting of Bureau Veritas (the 'Company'), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company's head office. Article content All resolutions submitted to the Shareholders' Meeting were adopted at a large majority, including: Article content The approval of the statutory and consolidated financial statements for the financial year ending on December 31, 2024, and the approval of a dividend distribution of €0.90 per share to be paid in cash on July 3, 2025 (ex-date on July 1, 2025) on positions closed on July 2, 2025; The approval of a related-party agreement concerning the Company's participation in Wendel's share placement (acquisition by the Company of its own shares); The approval of the report on Corporate Officers' compensation; The approval of fixed, variable and extraordinary components of the total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mr. Laurent Mignon, in his capacity as Chairman of the Board of Directors; The approval of fixed, variable and extraordinary components of total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mrs. Hinda Gharbi, in her capacity as Chief Executive Officer; The approval of the compensation policy for the Directors, the Chairman of the Board of Directors and the Chief Executive Officer for 2025; The authorization granted to the Board of Directors to trade in the Company's ordinary shares; The delegations and/or financial authorizations granted to the Board of Directors. Article content The Shareholders' Meeting renewed the term of office as Director of Mr. Laurent Mignon, and the Board of Directors reappointed him as Chairman of the Board of Directors. The Shareholders' Meeting also renewed the terms of office as Directors of Ms. Julie Avrane, Ms. Ana Giros Calpe and Mr. Jérôme Michiels. Ms. Lucia Sinapi-Thomas is leaving the Board, as her term of office has expired. The Directors commended her contribution to the Board's discussions and decisions, as well as to the work of its Committees. Article content To replace Ms. Sinapi-Thomas, the Shareholders' Meeting appointed Ms. Elodie Perthuisot as an independent director for a term of four years. Article content Elodie Perthuisot is a member of the Carrefour Group's Executive Committee and currently heads Carrefour Spain, one of the group's main subsidiaries. Holding an engineering degree from the École Polytechnique, she began her career in the public sector – she notably headed the office of Frédéric Mitterrand, Minister of Culture and Communication – before joining the retail sector, leading the commercial management and multichannel transformation of Fnac and then Fnac Darty. She joined Carrefour in 2018 where she has successively led the marketing in France, e-commerce and, since 2021, the group's digital and technological transformation. Under her leadership, Carrefour has significantly accelerated its digital and data ambitions, becoming a company recognized for its progress in these areas. Article content The Bureau Veritas Board of Directors will be able to rely on her diverse experience, and in particular on her expertise in digital transformation and operational management. Article content In the activity reports, Mrs. Hinda Gharbi, Chief Executive Officer, and Mr. François Chabas, Chief Financial Officer, presented the 2024 highlights, the 2024 financial results, providing specific details on revenue, adjusted operating profit, net earnings per share, cash flow statement and the financial position. Article content Mrs. Hinda Gharbi, Chief Executive Officer, then presented the review of the Group's activities for the 2024 financial year, and detailed the first quarter revenue as well as the 2025 outlook. She also provided an update on the LEAP I 2028 strategic plan. Article content Mr. Laurent Mignon and Mr. Pascal Lebard, Lead Independent Director, respectively presented corporate governance and compensation components of the Directors, the Chairman of the Board of directors and the Chief Executive Officer in 2024, as well as the compensation policies. Article content The broadcast of the Shareholders' Meeting, including the full presentation and the complete results of the vote of the resolutions, will be available on the Company's website ( Article content ABOUT BUREAU VERITAS Article content Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Article content Article content Article content Article content Contacts Article content ANALYST/INVESTOR CONTACTS Article content Article content Laurent Brunelle Article content Article content +33 (0)1 55 24 76 09 Article content Article content Article content Colin Verbrugghe Article content Article content +33 (0)1 55 24 77 80 Article content Article content Article content Karine Ansart Article content Article content Article content Inès Lagoutte Article content Article content Article content MEDIA CONTACTS Article content Article content Anette Rey Article content Article content +33 (0)6 69 79 84 88 Article content Article content Article content Article content Article content

CTV News

3 hours ago

• CTV News

PBO Yves Giroux on whether the government is on track to meet its fiscal targets

Politics Parliamentary Budget Officer Yves Giroux explains why it is difficult to assess the government's projected operating budget.

CBC

4 hours ago

• CBC

Should Canada loosen rules around foreign ownership of its airlines?

The Competition Bureau is calling for changes to improve the competitive landscape in Canada's airline industry, including loosening rules that limit foreign ownership of Canadian airlines. But would it work? We speak with two aviation experts with differing opinions on the issue.